BioIVT completed the acquisition of ZenBio.

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, completed the acquisition of ZenBio, an advanced cell products and services company. Financial terms were not disclosed. "Biospecimens and services like primary cell isolation are crucial for developing new pharmaceuticals. ZenBio's trusted reputation, combined with BioIVT's extensive portfolio and scalability, will allow us to deliver even more quality products and services to scientists and researchers around the world," Richard Haigh, BioIVT CEO.